Dipalmitoyl-phosphatidylserine-filled cationic maltodextrin nanoparticles exhibit enhanced efficacy for cell entry and intracellular protein delivery in phagocytic THP-1 cells
© 2023 the author(s), published by De Gruyter..
Vaccination through the upper respiratory tract is a promising strategy, and particulate antigens, such as antigens associated with nanoparticles, triggered a stronger immune response than the sole antigens. Cationic maltodextrin-based nanoparticles loaded with phosphatidylglycerol (NPPG) are efficient for intranasal vaccination but non-specific to trigger immune cells. Here we focused on phosphatidylserine (PS) receptors, specifically expressed by immune cells including macrophages, to improve nanoparticle targeting through an efferocytosis-like mechanism. Consequently, the lipids associated with NPPG have been substituted by PS to generate cationic maltodextrin-based nanoparticles with dipalmitoyl-phosphatidylserine (NPPS). Both NPPS and NPPG exhibited similar physical characteristics and intracellular distribution in THP-1 macrophages. NPPS cell entry was faster and higher (two times more) than NPPG. Surprisingly, competition of PS receptors with phospho-L-serine did not alter NPPS cell entry and annexin V did not preferentially interact with NPPS. Although the protein association is similar, NPPS delivered more proteins than NPPG in cells. On the contrary, the proportion of mobile nanoparticles (50%), the movement speed of nanoparticles (3 µm/5 min), and protein degradation kinetics in THP-1 were not affected by lipid substitution. Together, the results indicate that NPPS enter cells and deliver protein better than NPPG, suggesting that modification of the lipids of cationic maltodextrin-based nanoparticles may be a useful strategy to enhance nanoparticle efficacy for mucosal vaccination.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Biomolecular concepts - 14(2023), 1 vom: 01. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Brinkhuizen, Clément [VerfasserIn] |
---|
Links: |
---|
Themen: |
125709-33-3 |
---|
Anmerkungen: |
Date Completed 29.06.2023 Date Revised 29.06.2023 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1515/bmc-2022-0029 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM35878655X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM35878655X | ||
003 | DE-627 | ||
005 | 20231226075459.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1515/bmc-2022-0029 |2 doi | |
028 | 5 | 2 | |a pubmed24n1195.xml |
035 | |a (DE-627)NLM35878655X | ||
035 | |a (NLM)37377352 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Brinkhuizen, Clément |e verfasserin |4 aut | |
245 | 1 | 0 | |a Dipalmitoyl-phosphatidylserine-filled cationic maltodextrin nanoparticles exhibit enhanced efficacy for cell entry and intracellular protein delivery in phagocytic THP-1 cells |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.06.2023 | ||
500 | |a Date Revised 29.06.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 the author(s), published by De Gruyter. | ||
520 | |a Vaccination through the upper respiratory tract is a promising strategy, and particulate antigens, such as antigens associated with nanoparticles, triggered a stronger immune response than the sole antigens. Cationic maltodextrin-based nanoparticles loaded with phosphatidylglycerol (NPPG) are efficient for intranasal vaccination but non-specific to trigger immune cells. Here we focused on phosphatidylserine (PS) receptors, specifically expressed by immune cells including macrophages, to improve nanoparticle targeting through an efferocytosis-like mechanism. Consequently, the lipids associated with NPPG have been substituted by PS to generate cationic maltodextrin-based nanoparticles with dipalmitoyl-phosphatidylserine (NPPS). Both NPPS and NPPG exhibited similar physical characteristics and intracellular distribution in THP-1 macrophages. NPPS cell entry was faster and higher (two times more) than NPPG. Surprisingly, competition of PS receptors with phospho-L-serine did not alter NPPS cell entry and annexin V did not preferentially interact with NPPS. Although the protein association is similar, NPPS delivered more proteins than NPPG in cells. On the contrary, the proportion of mobile nanoparticles (50%), the movement speed of nanoparticles (3 µm/5 min), and protein degradation kinetics in THP-1 were not affected by lipid substitution. Together, the results indicate that NPPS enter cells and deliver protein better than NPPG, suggesting that modification of the lipids of cationic maltodextrin-based nanoparticles may be a useful strategy to enhance nanoparticle efficacy for mucosal vaccination | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a efferocytosis | |
650 | 4 | |a nanoparticle | |
650 | 4 | |a phospholipids | |
650 | 4 | |a targeting | |
650 | 4 | |a vaccine | |
650 | 7 | |a Phosphatidylserines |2 NLM | |
650 | 7 | |a maltodextrin |2 NLM | |
650 | 7 | |a 7CVR7L4A2D |2 NLM | |
650 | 7 | |a N-(3-pyridyl)-3-phenylsuccinimide |2 NLM | |
650 | 7 | |a 125709-33-3 |2 NLM | |
700 | 1 | |a Shapman, Damien |e verfasserin |4 aut | |
700 | 1 | |a Lebon, Alexis |e verfasserin |4 aut | |
700 | 1 | |a Bénard, Magalie |e verfasserin |4 aut | |
700 | 1 | |a Tardivel, Meryem |e verfasserin |4 aut | |
700 | 1 | |a Dubuquoy, Laurent |e verfasserin |4 aut | |
700 | 1 | |a Galas, Ludovic |e verfasserin |4 aut | |
700 | 1 | |a Carpentier, Rodolphe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biomolecular concepts |d 2010 |g 14(2023), 1 vom: 01. Jan. |w (DE-627)NLM206946481 |x 1868-503X |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:01 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.1515/bmc-2022-0029 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |e 1 |b 01 |c 01 |